Company intelligence / Profile preview

Soteria AI

San Francisco, California, United States

Ownership: Private
Employees: ~3
Development stage: Other

Overview

Developing switchable T-cell engagers using AbCID technology for safer cancer immunotherapy; preclinical optimization ongoing with $42M Series A funding.

Therapeutic areas: Oncology
Modalities: T cell therapyBispecific monoclonal antibody
Industry: Biotech

Partnerships

Roche Venture Fund5AM Ventures

Beyond the preview

Go deeper on Soteria AI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Soteria AI.

Explore the full profile